Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

Academic Article

Abstract

  • We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >or=1.6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.
  • Published In

  • Nature Medicine  Journal
  • Keywords

  • Anti-HIV Agents, Area Under Curve, CCR5 Receptor Antagonists, Clinical Trials, Phase II as Topic, Cyclohexanes, Dose-Response Relationship, Drug, HIV Infections, HIV-1, Humans, Maraviroc, RNA, Viral, Randomized Controlled Trials as Topic, Time Factors, Treatment Outcome, Triazoles, Viral Load
  • Digital Object Identifier (doi)

    Pubmed Id

  • 18545114
  • Author List

  • F√§tkenheuer G; Pozniak AL; Johnson MA; Plettenberg A; Staszewski S; Hoepelman AIM; Saag MS; Goebel FD; Rockstroh JK; Dezube BJ
  • Start Page

  • 1170
  • End Page

  • 1172
  • Volume

  • 11
  • Issue

  • 11